GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » 5-Year ROIIC %

NovMetaPharma Co (XKRX:229500) 5-Year ROIIC % : 178.59% (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. NovMetaPharma Co's 5-Year ROIIC % for the quarter that ended in Dec. 2024 was 178.59%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for NovMetaPharma Co's 5-Year ROIIC % or its related term are showing as below:

XKRX:229500's 5-Year ROIIC % is ranked better than
95.23% of 943 companies
in the Drug Manufacturers industry
Industry Median: 3.76 vs XKRX:229500: 178.59

NovMetaPharma Co 5-Year ROIIC % Historical Data

The historical data trend for NovMetaPharma Co's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co 5-Year ROIIC % Chart

NovMetaPharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,187.99 -30.29 -23.53 131.38 178.59

NovMetaPharma Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,187.99 -30.29 -23.53 131.38 178.59

Competitive Comparison of NovMetaPharma Co's 5-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, NovMetaPharma Co's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovMetaPharma Co's 5-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NovMetaPharma Co's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where NovMetaPharma Co's 5-Year ROIIC % falls into.


;
;

NovMetaPharma Co 5-Year ROIIC % Calculation

NovMetaPharma Co's 5-Year ROIIC % for the quarter that ended in Dec. 2024 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -5540.553 (Dec. 2024) - -12536.645 (Dec. 2019) )/( 5626.715 (Dec. 2024) - 1709.407 (Dec. 2019) )
=6996.092/3917.308
=178.59%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


NovMetaPharma Co  (XKRX:229500) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


NovMetaPharma Co 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of NovMetaPharma Co's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


NovMetaPharma Co Business Description

Traded in Other Exchanges
N/A
Address
727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co Headlines

No Headlines